MedTrace Logo

The Feasibility and Safety of an Intradialytic Exercise Program: DIALY-SIZE

NCT02234232 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-07-19

No results posted yet for this study

Summary

The primary aim of this pilot study is to evaluate the feasibility and safety of four different types of intradialytic exercise (exercise performed during dialysis) programs: resistance, aerobic, combined resistance and aerobic, and flexibility (attention control). The secondary aim of the study is to estimate the effect of aerobic and resistance exercise, each compared with the attention control on: health-related quality of life, tests of physical performance, strength, and physical activity outside of the dialysis unit. The results of this study will be used to inform the planning of a full-scale efficacy study.

Conditions

  • End-stage Renal Disease

Interventions

BEHAVIORAL

Exercise

Each exercise will be performed during the first 2.5 hours of the participant's hemodialysis session. Exercises are semi supervised: the kinesiologist will supervise the initial three exercise sessions, any session that requires a change to the exercise prescription and on a minimum of a weekly basis.

Sponsors & Collaborators

  • Alberta Innovates Health Solutions

    collaborator OTHER

  • University of Alberta

    lead OTHER

Principal Investigators

  • Stephanie Thompson, MD · University of Alberta

  • Scott Klarenbach, MD · University of Alberta

  • Marcello Tonelli, MD · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02234232 on ClinicalTrials.gov